Genmab A/S

Genmab A/S

World Rank (Aug-2026)
1196
Market Cap (Aug-2026)
20.955 Billion USD
World Rank (Jan-05-2024)
889
Market Cap (Jan-05-2024)
20.644 Billion USD
World Rank (Jul-30-2023)
718
Market Cap (Jul-30-2023)
26.119 Billion USD
World Rank (Jan-07-2022)
883
Market Cap (Jan-07-2022)
23.695 Billion USD
World Rank (Jan-01-2021)
696
Market Cap (Jan-01-2021)
26.503 Billion USD
Headquarters Country
Denmark
Top Healthcare Companies in Europe
CEO
Jan G. J. van de Winkel
Employee Count
1,660
Employee Count as of Date
As on 2022
World Region
Europe
World Subregion
Northern Europe
Annual Revenue in USD
3,720 Million USD
Annual Operating Income in USD
1,250 Million USD
Annual Net Income in USD
963 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
12,873 Million USD
Total Liabilities in USD
7,026 Million USD
Total Equity in USD
5,847 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Biotechnology
Company Website
GENMAB A/S
Wikipedia
Wikipedia
Yahoo
Yahoo @ Copenhagen
Company Profile

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Headquarters is in Denmark.

Annual Results Summary

GENMAB A/S - Yearly Revenue and Net Income - in Million DKK:

Year - EndingRevenueOperating IncomeNet Income
Dec-202214,5956,3575,522
Dec-20218,4823,0183,008
Dec-202010,1116,3134,758
Dec-20195,3662,6382,166
Balance Sheet Summary

Total Assets as on Dec-2022 was 30,278 Million DKK.

Total Liabilities as on Dec-2022 was 2,837 Million DKK.

Total Equity as on Dec-2022 was 27,441 Million DKK.

Founded Year
1999
Stock Category
S&P EUROPE 350
Stock Exchange
Nasdaq Nordic
Copenhagen

Share